Rates of CR/CRi, 12-month OS, and Kaplan-Meier survival plots for established and proposed AML prognostication systems for patients treated with venetoclax and azacitidine. (A) MRC 2010 cytogenetic risk.⁹ (B) ELN 2022 risk.²² (C) 4-gene prognostic signature proposed by Döhner et al, from VIALE-A study.⁷ (D) Molecular predictors of response and treatment failure, DiNardo et al.²³ (E) Mayo predictors of treatment response, Gangat et al.¹⁰